Abstract
Background: Isoproterenol (ISO) is a non-selective β-adrenergic agonist. Our aims were to investigate the autophagy and cell death pathways including apoptosis and necrosis in ISO-induced cardiac injury in a dosedependent manner.
Methods: Male Sprague-Dawley rats were treated for 24 hours with I. vehicle (saline); II. 0.005 mg/kg ISO; III. 0.05 mg/kg ISO; IV. 0.5 mg/kg ISO; V. 5 mg/kg ISO; VI. 50 mg/kg ISO, respectively. Hearts were isolated and infarct size was measured. Serum levels of Troponin T (TrT), lactate dehydrogenase (LDH), creatine kinase isoenzyme MB (CK-MB) were measured. TUNEL assay was carried out to monitor apoptotic cell death and Western blot was performed to evaluate the level of autophagic and apoptotic markers.
Results: Survival rate of animals was dose-dependently decreased by ISO. Serum markers and infarct size revealed the development of cardiac toxicity. Level of Caspase-3, and results of TUNEL assay, demonstrated that the level of apoptosis was dose-dependently increased. They reached the highest level in ISO 5 and it decreased slightly in ISO 50 group. Focusing on autophagic proteins, we found that level of Beclin-1 was increased in a dose-dependent manner, but significantly increased in ISO 50 treated group. Level of LC3B-II and p62 showed the same manner, but the elevated level of p62 indicated that autophagy was impaired in both ISO 5 and ISO 50 groups.
Conclusion: Taken together these results suggest that at smaller dose of ISO autophagy may cope with the toxic effect of ISO; however, at higher dose apoptosis is initiated and at the highest dose substantial necrosis occurs.
Keywords: Isoproterenol, cardiotoxicity, necrosis, apoptosis, autophagy, β-adrenergic agonist.
[http://dx.doi.org/10.1007/s12012-012-9196-5] [PMID: 23274852]
[http://dx.doi.org/10.1177/0192623307313010] [PMID: 18349426]
[http://dx.doi.org/10.1002/ptr.6152] [PMID: 30009418]
[http://dx.doi.org/10.1177/1753944714531638] [PMID: 24817146]
[http://dx.doi.org/10.1016/j.biopha.2017.08.009] [PMID: 28826162]
[http://dx.doi.org/10.1371/journal.pone.0111212] [PMID: 25369053]
[http://dx.doi.org/10.1007/s003950050195] [PMID: 9879436]
[http://dx.doi.org/10.1006/jmcc.1996.0193] [PMID: 8899559]
[http://dx.doi.org/10.1111/jcmm.13053] [PMID: 27997746]
[http://dx.doi.org/10.18632/oncotarget.16944] [PMID: 28445146]
[http://dx.doi.org/10.1371/journal.pone.0064757] [PMID: 23737997]
[http://dx.doi.org/10.1210/en.2007-0099] [PMID: 17395699]
[http://dx.doi.org/10.1074/jbc.M109.024406] [PMID: 19696026]
[http://dx.doi.org/10.1016/j.trsl.2016.03.002] [PMID: 27016702]
[http://dx.doi.org/10.1038/nrm2239] [PMID: 17717517]
[http://dx.doi.org/10.1016/j.molcel.2010.09.023] [PMID: 20965422]
[http://dx.doi.org/10.1038/nature04961] [PMID: 16810246]
[http://dx.doi.org/10.1161/01.RES.81.2.137] [PMID: 9242174]
[http://dx.doi.org/10.1097/00005344-199003000-00009] [PMID: 1691363]
[http://dx.doi.org/10.1016/j.ab.2012.10.010] [PMID: 23085117]
[http://dx.doi.org/10.1177/1074248414539564] [PMID: 24950765]
[PMID: 19712573]
[http://dx.doi.org/10.1172/JCI118909] [PMID: 8787689]
[http://dx.doi.org/10.1186/1471-2261-12-63] [PMID: 22867422]
[http://dx.doi.org/10.1038/nrm3735] [PMID: 24401948]
[http://dx.doi.org/10.1016/j.molcel.2009.01.021] [PMID: 19250912]
[http://dx.doi.org/10.1016/j.cell.2010.01.028] [PMID: 20144757]
[http://dx.doi.org/10.1186/s11658-016-0031-z] [PMID: 28536631]
[http://dx.doi.org/10.1111/bcp.12726] [PMID: 26183037]
[http://dx.doi.org/10.1016/S0008-6363(97)00212-5] [PMID: 9539862]
[http://dx.doi.org/10.1016/j.biopha.2018.09.055] [PMID: 30245462]